A Multicountry, Multicentre, Non-interventional, Retrospective Study to Determine Real-world Treatment Patterns and Associated Outcomes After First Line Osimertinib in Patients With Advanced and Metastatic NSCLC EGFRm in the GCC Region

Prior treatment

• Patients who received curative CRT within 3 months and/or any first-line systemic anti-cancer therapies (SACT) for advanced/metastatic NSCLC for \>28 days prior to Osimertinib start.
• Patients who have prior exposure of I/O therapy.

Other illness

• Failure to meet one or more of the inclusion criteria.

Other

• Subjects are not eligible for this study if they fulfil any of the following exclusion criteria:

• For inclusion in the study, all the following inclusion criteria must be fulfilled:
• Patients with Stage IIIB-IV NSCLC using either AJCC 7th or 8th edition with EGFR mutation.
• Age 18 or older at index date (specific age may vary according to country-specific guidelines)
• Treated in the first line with Osimertinib from (April 1st, 2018, until December 31st, 2021).
• Medical records available at the participating site reflect at least 9 months of follow-up from the index date (unless the patient died within the first 9 months of diagnosis).
  • Note: specific databases may have additional inclusion criteria which will be detailed in country-specific protocol adaptations and statistical analysis plans (SAPs).